PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Inclusion Criteria: * Participant must have a diagnosis of moderate or severe COPD. * Participant must have a post-bronchodilator FEV1/forced vital capacity (FVC) ratio \< 0.7. * Participant must have a post-bronchodilator FEV1 % predicted value ≥ 30% and \< 70%. * Participant must be between 40 and 80 years of age, of either sex, and of any race. * Participant must be a current or ex-smoker, with a cigarette smoking history of ≥ 10 years or \> 10 pack-years. Exclusion Criteria: * Participant has been diagnosed with asthma or other clinically relevant lung disease other than COPD (e.g. restrictive lung diseases, sarcoidosis, tuberculosis, idiopathic pulmonary fibrosis, bronchiectasis, or lung cancer). * Participant has been diagnosed with α1-antitrypsin deficiency. * Participant has a body mass greater than 150 kg (330 lb) or less than 40 kg (88 lb). * Participant has active infection. * Participant has had a significant exacerbation of COPD or has required mechanical ventilation within 4 weeks of screening. * The participant with clinically relevant uncontrolled medical condition not associated with COPD. * Participant has documented history of uncontrolled heart failure. * Participant has pulmonary hypertension due to left heart condition. * Participant has atrial fibrillation or significant congenital heart defect/disease. * Participant has initiated pulmonary rehabilitation within 3 months of screening. * Participant is allergic to bovine or porcine products. * Participant has evidence of active malignancy, or prior history of active malignancy that has not been in remission for at least 5 years. * Participant has a life expectancy of \< 6 months.